...dominating the immuno-oncology space. Armed with $79 million in series A and B funds, the Flexus Biosciences Inc.... ...targeting Tregs and myeloid-derived suppressor cells Disease focus: Cancer Clinical status: Preclinical Founded: 2015 by Flexus Biosciences Inc.... ...at the annual meeting of the American Association for Cancer Research (2017)
Karen Tkach Tuzman, Senior Writer
Flexus Biosciences Inc.
RAPT...
...dominating the immuno-oncology space. Armed with $79 million in series A and B funds, the Flexus Biosciences Inc.... ...targeting Tregs and myeloid-derived suppressor cells Disease focus: Cancer Clinical status: Preclinical Founded: 2015 by Flexus Biosciences Inc.... ...at the annual meeting of the American Association for Cancer Research (2017)
Karen Tkach Tuzman, Senior Writer
Flexus Biosciences Inc.
RAPT...